Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Join an expert panel for a webinar on Smart investments for a secure retirement January 28, 2021. Register now!
you are here: HomeNewsIndia

COVID-19 Vaccine Update: Recipients cannot choose between Covishield and Covaxin initially

The Drugs Controller General of India (DCGI) had recently granted emergency use authorisation to two COVID-19 vaccines – Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin.

January 13, 2021 / 04:00 PM IST
Representative image

Representative image

India is set to launch its COVID-19 vaccination drive from January 16 with two vaccines -- Covishield and Covaxin – but the recipients will not be given the option to choose between the two, signalled the Union health ministry.

The Drugs Controller General of India (DCGI) had recently granted emergency use authorisation to two COVID-19 vaccines – Covishield, developed by Oxford University and British-Swedish company AstraZeneca and manufactured by the Serum Institute of India (SII) and Bharat Biotech's Covaxin.

With the vaccinations scheduled to begin on January 16 starting with healthcare and frontline workers in the first phase, the Centre has said that all the vaccine vials -- 1.1 crore of Covishield from the Serum Institute of India and 55 lakh of Covaxin from Bharat Biotech -- will be received by January 14.

Ahead of the vaccination drive, there seems to be expectations among many that they would receive the AstraZeneca-Oxford vaccine in India instead of the homegrown Covaxin. Asked if the recipients would have the option to choose between the two vaccines, Union Health Secretary Rajesh Bhushan said, "There is no such option available to any of the beneficiaries in any country."

This means people will not get to choose the vaccine they will be administered. They can get either of the two COVID-19 vaccines that have got emergency use approval in India.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

Bhushan asserted that both vaccines are safe and generate immune responses against the novel coronavirus.

Dr VK Paul member, NITI Aayog member (Health), said these two vaccines have been tested in thousands of people, they are the safest and there is no risk of any significance.

Also read | India yet to decide on giving indemnity to COVID-19 vaccine makers

The vaccination drive in the country in what Prime Minister Narendra Modi has called the world's largest inoculation programme with priority to be given to nearly three crore healthcare and frontline workers.

In India, four more COVID-19 vaccines, one by Zydus Cadila, Russian vaccine Sputnik V, Biological E, and Gennova, are in advanced clinical trials in India, said Bhushan. "In the coming days you may see some of these vaccine manufacturers too approaching the drug controller for emergency use authorisation," he added.

Also read | India's COVID-19 vaccine: Who'll get it, when and how - All you need to know

India's COVID-19 caseload has increased to 1,04,95,147 with 15,968 infections being reported in a day, while the recoveries have surged to 1,01,29,111 pushing the national recovery rate to 96.51 percent, according to the Union Health Ministry data updated on January 13. The death toll increased to 1,51,529 with 202 daily new fatalities, the data showed. There are 2,14,507 active cases of coronavirus infections in the country, which comprises 2.04 percent of the total caseload, the data stated.

(With inputs from PTI)

Follow our full coverage on COVID-19 here.
Moneycontrol News
first published: Jan 13, 2021 02:07 pm

stay updated

Get Daily News on your Browser
Sections